Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 216

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 216
---
 discussions with the management of the Company, the Board has determined that it is advisable 
 and in the best interests of the Company and its stockholders to further amend the Plan,      
 as amended (“Amendment #2”), to reduce the maximum number of shares reserved                  
 for issuance under the Plan from 20,000,000 shares of Common Stock to 10,000,000 shares of    
 Common Stock. Amendment No. 2 became effective on the date of the approval by the Board of    
 Directors, but it is subject to approval by the Company’s shareholders within 12 months,      
 pursuant to section 422(b)(1) of the Internal Revenue Code.                                   |

| c. | On December 31, 2024, the Board                                                             
 approved a grant under the Company’s Global Share Incentive Plan (2021) to an employee      
 of the Predecessor of 740,000 stock options at an exercise price of $0.30 per share. Of the 
 options granted, options for 560,000 shares were fully vested upon grant and the remaining  
 180,000 options are to be vest on April 10, 2025. The options exercisable within ten years  
 from grant date.                                                                            |

<div align='center'>F-27</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

The fair value of the successor’s
share options granted during the period commencing July 24, 2024 through December 31, 2024 was estimated using the black Scholes model
using the following range assumptions:

| Description             |     | December 31, 
 2024         |       |   |
|:------------------------|:----|:-------------|------:|:--|
| Risk-free interest rate |     |              |  4.51 | % |
| Expected volatility     |     |              | 105.6 | % |
| Dividend yield          |     |              |     0 |   |
| Expected term           |     |              |    10 |   |
| Exercise price (USD)    |     |              |   0.3 |   |

| d. | On December 31,                                                                       
 2024, Company’s president and Chief Operating Officer exercised 2,800,000 option into 
 2,